Author | Manfred Welslau, MD | OncLive

Author | Manfred Welslau, MD

Articles

Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL

June 29, 2020

Video

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Dr. Welslau on REFLECT Interim Safety Analysis in DLBCL

September 20, 2019

Video

Manfred Welslau, MD, discusses the first interim safety analysis in treatment-naïve, CD20-positive diffuse large B-cell lymphoma following the approval of Rixathon, a Sandoz biosimilar for rituximab.

Dr. Welslau on the Rationale for the REFLECT Trial in DLBCL

September 19, 2019

Video

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the REFLECT trial in diffuse large B-cell lymphoma.

Dr. Welslau on Financial Savings of Biosimilar Rituximab in DLBCL

August 30, 2019

Video

Manfred Welslau, MD, discusses financial savings of using a rituximab biosimilar for patients with previously untreated CD20-positive diffuse large B-cell lymphoma.

x